Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K 2 analog

International Journal of Hematology

Volumn 69, Issue 1, 1999, Pages 24-26

  Takami, Akiyoshi ^a,b   Nakao, Shinji ^c   Ontachi, Yasuo ^a   Yamauchi, Hiromasa ^a   Matsuda, Tamotsu ^c  

^a Kurobe City Hospital   (Japan)

^b ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Menatetrenone; Myelodysplastic syndrome; Vitamin K 2

Indexed keywords

CALCIFEDIOL; DRUG DERIVATIVE; FARNOQUINONE; MENATETRENONE; VITAMIN K GROUP;

AGED; APOPTOSIS; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; REFRACTORY ANEMIA;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; APOPTOSIS; CALCIFEDIOL; CELL DIFFERENTIATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN K; VITAMIN K 2;

EID: 0032600021     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Oguma S, Yoshida Y, Uchino H, Okuma M, Maekawa T, Nomura T. Re-analysis of prognosis in refractory anemia alone, with ring sideroblasts, and with excess of blasts. Int J Hematol 1993;57:15-25.
2. Yoshida Y, Okuma M, Uchino H. Current state of differentiation therapy in myelodysplasias. In: Waxman S, Rossi GB, Takaku F, editors. The Status of Differentiation Therapy of Cancer, Volume 2. New York: Raven Press, 1991;441-6.
3. 2: a potent inducer of differentiation of various human myeloid cell lines. Biochem Bioph Res 1994;205:1305-10.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
5. Liu Y, Nelson AN, Lipsky JJ. Vitamin K-dependent carboxylase: mRNA distribution and effects of vitamin K-deficiency and warfarin treatment. Biochem Biophys Res 1996;224:549-54.
6. 2 and its derivatives induce apoptosis in leukemic cells and enhance the effect of all-trans retinoic acid. Leukemia 1997;11:779-87.